- Home
- ACRS vs MITT Comparison
ACRS vs MITT Comparison
Compare ACRS & MITT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACRS
- MITT
- Stock Information
- Founded
- ACRS 2012
- MITT 2011
- Country
- ACRS United States
- MITT United States
- Employees
- ACRS N/A
- MITT N/A
- Industry
- ACRS Biotechnology: Pharmaceutical Preparations
- MITT Real Estate Investment Trusts
- Sector
- ACRS Health Care
- MITT Real Estate
- Exchange
- ACRS Nasdaq
- MITT Nasdaq
- Market Cap
- ACRS 198.2M
- MITT 230.0M
- IPO Year
- ACRS 2015
- MITT 2011
- Fundamental
- Price
- ACRS $2.26
- MITT $7.68
- Analyst Decision
- ACRS Strong Buy
- MITT Strong Buy
- Analyst Count
- ACRS 9
- MITT 5
- Target Price
- ACRS $9.25
- MITT $8.60
- AVG Volume (30 Days)
- ACRS 1.5M
- MITT 176.0K
- Earning Date
- ACRS 11-06-2025
- MITT 11-04-2025
- Dividend Yield
- ACRS N/A
- MITT 10.94%
- EPS Growth
- ACRS N/A
- MITT N/A
- EPS
- ACRS N/A
- MITT 0.86
- Revenue
- ACRS $16,789,000.00
- MITT $83,509,000.00
- Revenue This Year
- ACRS N/A
- MITT N/A
- Revenue Next Year
- ACRS N/A
- MITT $14.27
- P/E Ratio
- ACRS N/A
- MITT $8.95
- Revenue Growth
- ACRS N/A
- MITT 25.02
- 52 Week Low
- ACRS $1.05
- MITT $5.63
- 52 Week High
- ACRS $5.17
- MITT $7.97
- Technical
- Relative Strength Index (RSI)
- ACRS 53.36
- MITT 63.20
- Support Level
- ACRS $2.24
- MITT $7.00
- Resistance Level
- ACRS $2.70
- MITT $7.49
- Average True Range (ATR)
- ACRS 0.23
- MITT 0.19
- MACD
- ACRS 0.01
- MITT 0.06
- Stochastic Oscillator
- ACRS 46.34
- MITT 90.67
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.
About MITT AG Mortgage Investment Trust Inc.
AG Mortgage Investment Trust Inc is a real estate investment trust (REIT). It focuses on investing in a diversified risk-adjusted portfolio of residential mortgage-related assets in the U.S. mortgage market. Its objective is to provide attractive risk-adjusted returns to its stockholders over the long term through dividends and capital appreciation. It also focuses on investing in residential mortgage-backed securities (RMBS) issued or guaranteed by a government-sponsored enterprise.